Recilisib sodium

CAS : 922139-31-9

Ref. 3D-XLB13931

Informations sur le produit

• Nom: Recilisib sodium
• Synonymes: Ex-Rad, ON 01210.Na, Benzoic acid, 4-[(1E)-2-[[(4-chlorophenyl)methyl]sulfonyl]ethenyl]-, sodium salt (1:1), Sodium 4-[(1E)-2-[[(4-chlorophenyl)methyl]sulfonyl]ethenyl]benzoate (1:1)

Description

Recilisib sodium is an experimental drug that is being studied for its potential use in the treatment of various cancers. It has been shown to kill cancer cells by targeting a specific protein, pro-apoptotic protein Bax, which is found only on the surface of tumor cells. Recilisib sodium binds to Bax and prevents it from activating other proteins in the apoptosis pathway, leading to cell death. Recilisib sodium has a low bioavailability and can only be used as a diagnostic agent. The drug is being evaluated for its use as a diagnostic tool for identifying cancer cells in blood samples from pregnant women or fetuses.
Recilisib sodium has also been shown to have therapeutic effects against toxic epidermal necrolysis (TEN), which is a severe form of skin inflammation often caused by exposure to some types of drugs or radiation. The drug was able to reduce lesions and improve symptoms in animal models with TEN.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 358.8 g/mol
• Formule: C₁₆H₁₂ClNaO₄S
• Degré de pureté: Min. 95%